Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics

Abstract

Long-term follow-up data of patients with schizophrenia on depot antipsychotics have been few and the longest follow-up period has been up to 7 years. We carried out a systematic chart review to examine 10-year outcomes for outpatients with schizophrenia who were receiving a conventional depot antipsychotic. Maintenance of outpatient status for 10 years was considered as a favorable outcome. From the initial sample of 1587 outpatients, 90 patients who were receiving a depot antipsychotic were included in this study (mean±SD, age 44.0±13.0 years; men, N=54). Haloperidol decanoate, fluphenazine decanoate, fluphenazine enanthate, and haloperidol decanoate plus fluphenazine enanthate were used in 53 (58.9%), 29 (32.2%), seven (7.8%), and one (1.1%) patients, respectively. These depot antipsychotics accounted for 36.9% of the total antipsychotic dosage on average. Seventeen patients (18.9%) successfully maintained outpatient status for 10 years. The most frequent reason for dropout was 'hospitalization' (N=49, 54.4%), followed by 'referral to another clinic/hospital' (N=9, 10.0%) and 'side effects' (N=7, 7.8%). As only 36.9% of the chlorpromazine equivalents were administered through depot antipsychotics, it is difficult to draw any firm conclusion. Still, the data suggest that even depot antipsychotics may not sufficiently prevent relapse in the treatment of schizophrenia.

Spatial distribution of oil depots monitored in human muscle using MRI

“…Sustained delivery of drugs is an important method of drug administration for a number of diseases that require long-term drug treatment, such as psychiatric disorders (Covell et al, 2012;Novakovic et al, 2013;Uchida et al, 2013;Van Weringh et al, 1994) and hormone-dependent conditions (Edelstein and Basaria, 2010;Geusens, 1995;Morgentaler et al, 2008). The most commonly used drug-delivery systems, which can release drugs for a longer period of time, are parenteral injections.…”

Longitudinal changes in clozapine dose in patients with treatment-resistant schizophrenia: a 5-year retrospective cohort study

“…Recent clinical guidelines on antipsychotic maintenance treatment in schizophrenia recommend reducing the dose used in acute treatment (Shimomura et al , 2020). In clinical practice, once acute symptoms have been stabilized, clinicians frequently attempt to reduce the doses of antipsychotics to lower the risk of side effects such as somnolence, sedation and extrapyramidal symptoms (Takeuchi et al , 2011); however, only a few studies have examined long-term antipsychotic dose changes in the maintenance treatment of schizophrenia (Margolese et al , 2002; Hermes and Rosenheck, 2012; Uchida et al , 2013; Ikai et al , 2016; Ringen et al , 2019; Nakajima et al , 2021).…”

Tratamiento con antipsicóticos de depósito del paciente adulto con diagnóstico de esquizofrenia

“…La evidencia de si los APD aumentan la adherencia y disminuyen las recaí-das y rehospitalizaciones no es consistente 3,[7][8][9] . Hay estudios que muestran que los APD pueden aumentar la tasa de adherencia en pacientes con esquizofrenia 7,10 , pero el aumento de adherencia no necesariamente se refleja en una disminución significativa de las tasas de recaída o rehospitalización en el largo plazo 9 . Por otra parte, es importante tener en cuenta que los APD pueden tener efectos secundarios tales como complicaciones en el sitio de inyección: dolor, sangrado, hematoma, nódulos transitorios, y efectos extrapiramidales más prolongados, especialmente disquinesia tardía.…”